NasdaqGM - Nasdaq Real Time Price USD
Iovance Biotherapeutics, Inc. (IOVA)
1.8250
+0.1650
+(9.94%)
As of 3:55:53 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 11 |
| Avg. Estimate | -0.28 | -0.25 | -1.09 | -0.75 |
| Low Estimate | -0.36 | -0.34 | -1.42 | -1.14 |
| High Estimate | -0.2 | -0.18 | -0.87 | -0.12 |
| Year Ago EPS | -0.34 | -0.28 | -1.28 | -1.09 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 12 | 12 |
| Avg. Estimate | 66.65M | 78.22M | 285.71M | 473.56M |
| Low Estimate | 55.16M | 73.81M | 261.65M | 357.8M |
| High Estimate | 75.9M | 84.01M | 300.4M | 634.1M |
| Year Ago Sales | 31.11M | 58.55M | 164.07M | 285.71M |
| Sales Growth (year/est) | 114.27% | 33.58% | 74.14% | 65.75% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.35 | -0.3 | -0.27 | -0.23 |
| EPS Actual | -0.34 | -0.28 | -0.26 | -0.36 |
| Difference | 0.01 | 0.02 | 0.01 | -0.13 |
| Surprise % | 3.71% | 7.20% | 2.85% | -56.30% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.28 | -0.25 | -1.09 | -0.75 |
| 7 Days Ago | -0.26 | -0.23 | -0.99 | -0.53 |
| 30 Days Ago | -0.21 | -0.18 | -0.78 | -0.33 |
| 60 Days Ago | -0.22 | -0.19 | -0.8 | -0.36 |
| 90 Days Ago | -0.23 | -0.2 | -0.86 | -0.25 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 2 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | 1 | 1 | 1 | 8 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| IOVA | 18.38% | 9.19% | 14.88% | 31.48% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Downgrade | UBS: Buy to Neutral | 5/16/2025 |
| Maintains | Goldman Sachs: Buy to Buy | 5/12/2025 |
| Maintains | Mizuho: Outperform to Outperform | 5/12/2025 |
| Maintains | Barclays: Overweight to Overweight | 5/12/2025 |
| Downgrade | JMP Securities: Market Outperform to Market Perform | 5/9/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/9/2025 |
Related Tickers
VKTX Viking Therapeutics, Inc.
27.53
-3.18%
AXSM Axsome Therapeutics, Inc.
108.28
+0.69%
IBRX ImmunityBio, Inc.
2.8150
-0.88%
SRPT Sarepta Therapeutics, Inc.
37.91
+4.06%
TGTX TG Therapeutics, Inc.
34.90
+1.57%
MDGL Madrigal Pharmaceuticals, Inc.
290.45
-0.18%
SMMT Summit Therapeutics Inc.
23.92
+0.21%
ALT Altimmune, Inc.
5.49
-1.70%
BLUE bluebird bio, Inc.
4.9750
+0.10%
NTLA Intellia Therapeutics, Inc.
9.04
+6.29%